Regulatory


Comparator A 8


lmost by definition, clinical trials are about learning something new; about grasping into the unknown and discovering how a novel drug could change the world. Just consider the sector’s experience with Covid-19, and how in 2021 the World Health Organisation emphasised how globalised trials were crucial in developing a “new global approach” to fight the disease. Of course,


sourcing


Comparator drugs are a crucial part of clinical trials everywhere; helping researchers understand exactly how their inventions fare against the competition, or even when drugs can work together to offer subjects something new. Yet, with supply chains and international regulations to contend with, the life of a comparator drug expert is far from straightforward. Andrea Valentino talks to Tom White at Bionical Emas and Terrence Walsh at Regeneron to understand more, and along the way explores how technology and collaboration could make comparators far easier to access.


that’s before you consider the financial benefits of new medications. According to work by the Peoples Vaccine Alliance, the Covid-19 vaccines together made Pfizer, BioNTech and Moderna an estimated $93.5m every single day, or about $1,000 every minute. Reflected by similar statistics across the industry as a whole – the global drug discovery market is expected to reach $161bn by the end of


Clinical Trials Insight / www.worldpharmaceuticals.net


gob_cu/Shutterstock.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45